Decitabine/Selinexor: Lack of efficacy, digestive tract side effects and off label use: case report.

A 67-year-old man with atypical chronic myeloid leukaemia (aCML) showed lack of efficacy with decitabine treatment and experienced digestive tract side effects from off-label use of selinexor. Despite initial improvement with hydroxycarbamide, his condition worsened with decitabine, leading to a diagnosis of progressive disease. The patient refused stem cell transplantation and opted for selinexor, which initially caused side effects but ultimately resulted in partial improvement after eight cycles of combination therapy with azacitidine. [Extracted from the article]